Effect of itraconazole on the pharmacokinetics of imidafenacin in healthy subjects

Journal of Clinical Pharmacology

Volumn 48, Issue 3, 2008, Pages 330-334

  Ohno, Tomoya ^a   Nakayama, Kazuki ^a   Nakade, Susumu ^a   Kitagawa, Junsaku ^a   Ueda, Shinya ^a   Miyabe, Hiroyuki ^a   Miyata, Yasuyuki ^a   Ohnishi, Akihiro ^b  

^a ONO PHARMACEUTICAL CO   (Japan)

^b JIKEI UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

Drug drug interaction; Human; Imidafenacin; Itraconazole; Pharmacokinetics

Indexed keywords

CYTOCHROME P450 3A4; DRUG METABOLITE; IMIDAFENACIN; ITRACONAZOLE;

ADULT; AREA UNDER THE CURVE; ARTICLE; CLINICAL TRIAL; CONFIDENCE INTERVAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG BLOOD LEVEL; DRUG DETERMINATION; DRUG EFFECT; DRUG METABOLISM; DRUG SAFETY; DRUG TOLERABILITY; ENZYME INHIBITION; HEADACHE; HUMAN; HUMAN EXPERIMENT; LEUKOCYTE COUNT; LIQUID CHROMATOGRAPHY; LYMPHOCYTE COUNT; MAXIMUM PLASMA CONCENTRATION; NEUTROPHIL COUNT; NORMAL HUMAN; SIDE EFFECT; SINGLE DRUG DOSE; TANDEM MASS SPECTROMETRY;

ADMINISTRATION, ORAL; ADULT; AREA UNDER CURVE; CHROMATOGRAPHY, LIQUID; CYTOCHROME P-450 CYP3A; DRUG INTERACTIONS; HEADACHE; HUMANS; IMIDAZOLES; ITRACONAZOLE; METABOLIC CLEARANCE RATE; MUSCARINIC ANTAGONISTS; PATIENT DROPOUTS; TABLETS; TANDEM MASS SPECTROMETRY;

EID: 39149118864     PISSN: 00912700     EISSN: 15524604     Source Type: Journal    
DOI: 10.1177/0091270007310386     Document Type: Article

References (14)

1. Abrams P., Cardozo L., Fall M., et al. The standardization of terminology in lower urinary tract function: report from the standardization sub-committee of the international continence society. Urology. 2003 ; 61: 37-49.
2. Jackson S. The patient with an overactive bladder-symptoms and quality of life issues. Urology. 1997 ; 50: 18-24.
3. Liberman JN, Hunt TL, Stewart WF, et al. Health-related quality of life among adults with symptoms of overactive bladder: results from a US community-based survey. Urology. 2001 ; 57: 1044-1050.
4. Stewart WF, Van Rooyen JB, Cundiff GW, et al. Prevalence and burden of overactive bladder in the United States. World J Urol. 2003 ; 20: 327-336.
5. Margalith I., Gillon G., Gordon D. Urinary incontinence in women under 65: quality of life, stress related to incontinence and patterns of seeking health care. Qual Life Res. 2004 ; 13: 1381-1390.
6. Hu TW, Wagner TH, Bentkover JD, et al. Estimated economic costs of overactive bladder in the United States. Urology. 2003 ; 61: 1123-1128.
7. Wein AJ, Rovner ES The overactive bladder: an overview for primary care health providers. Int J Fertil Womens Med. 1999 ; 44: 56-66.
8. Ohno T., Nakade S., Nakayama K., et al. Absolute bioavailability of imidafenacin after oral administration to healthy subjects. Br J Clin Pharmacol. In press.
9. Ohmori S., Miura M., Toriumi C., et al. Absorption, metabolism and excretion of [14C]imidafenacin, a new compound for treatment of overactive bladder, following oral administration to healthy male subjects. Drug Metab Dispos. 2007 ; 35: 1624-1633.
10. Kanayama N., Kanari C., Masuda Y., et al. Drug-drug interactions in the metabolism of imidafenacin: role of the human cytochrome P450 enzymes and UDP-glucuronic acid transferases, and potential of imidafenacin to inhibit human cytochrome P450 enzymes. Xenobiotica. 2007 ; 37: 139-154.
11. Masuda Y., Kanayama N., Manita S., et al. Development and validation of bioanalytical methods for imidafenacin (KRP-197/ ONO-8025) and its metabolites in human plasma by liquid chromatography-tandem mass spectrometry. J Chromatogr B. 2007 ; 853: 70-79.
12. US Food and Drug Administration. Guidance for Industry: In Vivo Drug Metabolism/Drug Interaction Studies-Study Design, Data Analysis, and Recommendations for Dosing and Labeling. Rockville, MD: Food & Drug Administration ; 1999.
13. Bjornsson TD, Callaghan JT, Einolf HJ, et al. The conduct of in vitro and in vivo drug-drug interaction studies: a Pharmaceutical Research and Manufacturers of America (PhRMA) perspective. Drug Metab Dispos. 2003 ; 31: 815-832.
14. Miyata T., Takanaga H., Matsuo H., et al. P-glycoprotein-mediated transport of itraconazole across the blood-brain barrier. Antimicrob Agents Chemother. 1998 ; 42: 1738-1744.